Results
|
|
1.
|
Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. MedStar authors:
Year: 2019
Citation: - The Lancet Diabetes & Endocrinology. 7(8):596-605, 2019 08.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Gonzalez-Galvez G, Gron R, Halladin N, Haluzik M, Jermendy G, Kok A, Orsy P, Sabbah M, Sesti G, Silver R
|
|
|
2.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(9):1579-86, 2016 Sep
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Diamant M, Fonseca V, LixiLan PoC Study Group, Perfetti R, Rosenstock J, Silvestre L, Souhami E, Zhou T
|
|
|
3.
|
Reverse Remodeling Effects of Sacubitril-Valsartan: Structural and Functional Optimization in Stage C Heart Failure. MedStar authors:
Year: 2024
Citation: - American Journal of Cardiology. 210:249-255, 2024 Jan 01.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Kalanatari S, Oren D, Medvedofsky D, Narang A, Imamura T, Tayazime S, Kim GH, Raikhelkar J, Sayer G, Lang RM, Uriel N
|
|
|
4.
|
|
|
|
5.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
6.
|
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. MedStar authors:
Year: 2016
Citation: - Diabetes Care. 39(11):1972-1980, 2016 Nov
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bellido D, Bergenstal RM, Gonzalez-Galvez G, Guo H, LixiLan-L Trial Investigators, Niemoeller E, Rosenstock J, Souhami E, Takami A, Unger J, Wysham C
|
|
|
7.
|
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(11):2108-2116, 2019 11.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Blonde L, Del Prato S, Frias J, Henry R, Ji C, Niemoeller E, Rosenstock J, Shehadeh N, Souhami E
|
|
|
8.
|
|
|
|
9.
|
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. MedStar authors:
Year: 2021
Citation: - Hepatology. 74(6):2952-2964, 2021 12.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Darling JM, Di Bisceglie A, Dong M, Evon DM, Fishbein DA, Fried MW, Hinestrosa F, Horne PM, Khalili M, Kixmiller S, Lok AS, Michael L, Moon JS, Morelli G, Muir AJ, Nelson DR, Pearlman B, Peter J, PRIORITIZE Study Team, Rajender Reddy K, Segal JB, Sherman KE, Shiffman ML, Sloan A, Stewart PW, Sulkowski MS, Vainorius M, Wadsworth S
|
